Comparative Pharmacology
Head-to-head clinical analysis: FLUCONAZOLE versus POSACONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUCONAZOLE versus POSACONAZOLE.
Fluconazole vs POSACONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluconazole is a triazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane.
Posaconazole inhibits fungal CYP450-dependent 14α-demethylase, blocking ergosterol synthesis, disrupting fungal cell membrane integrity and function.
200-400 mg orally or intravenously once daily. For candidemia and other invasive Candida infections, loading dose of 800 mg (12 mg/kg) on day 1, then 400 mg (6 mg/kg) daily.
300 mg orally twice daily on day 1, then 300 mg once daily thereafter. Extended-release tablets: 300 mg orally twice daily on day 1, then 300 mg once daily. Intravenous: 300 mg IV twice daily on day 1, then 300 mg once daily.
MODERATE Risk
MODERATE Risk
Clinical Note
moderatePosaconazole + Tranilast
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Tranilast."
Clinical Note
moderatePosaconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Tolfenamic acid."
Clinical Note
moderatePosaconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Nimesulide."
Clinical Note
moderateTerminal elimination half-life ~30 hours (range 20-50 h) in patients with normal renal function; prolonged in renal impairment (up to 98 h in CrCl <20 mL/min). This long half-life supports once-daily dosing and allows loading dose administration.
Terminal elimination half-life: 35 hours (range 25–50 hours), allowing once-daily dosing after steady state; prolonged in hepatic impairment.
Renal: approximately 80% as unchanged drug; biliary/fecal: ~11% as metabolites and unchanged drug.
Fecal (77% as unchanged drug) and renal (14% as glucuronide conjugates); <1% excreted unchanged in urine.
Category C
Category C
Azole Antifungal
Azole Antifungal
Posaconazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Risedronic acid."